Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $40
Canaccord Genuity analyst Maria Ripps maintains Hims & Hers Health (NYSE: HIMS ) with a Buy and raises the price target from $32 to $40.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.